Khloris Biosciences

Executive Summary

Khloris Biosciences is a private biotechnology company pioneering a novel class of anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs). Founded in 2018 and headquartered in San Francisco, the company has partnered with Leaps by Bayer, the investment arm of Bayer, to advance this first-in-class platform. The technology leverages iPSCs to generate personalized cancer vaccines that could train the immune system to recognize and eliminate tumor cells, potentially preventing recurrence and even primary disease. This approach addresses a critical unmet need in oncology: durable, long-lasting immune responses against a broad range of cancers. Khloris's iPSC-based platform is designed to be scalable and cost-effective, differentiating it from traditional cell therapies. While the company remains in early development stages, the collaboration with a global life sciences leader like Bayer provides significant validation and resources. The market potential is substantial if clinical proof-of-concept is achieved, positioning Khloris as an emerging player in the cancer immunotherapy landscape. Key risks stem from the novelty of the platform and the challenges of demonstrating efficacy and safety in human trials.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Proof-of-Concept Data from iPSC Vaccine Program60% success
• Q3 2027IND Filing for Lead Candidate50% success
• TBDExpansion of Bayer Partnership or Additional Strategic Collaboration40% success